Abstract
BackgroundIn Estonia, women have much longer life expectancy than men. The aim of this study was to examine sex differences in cancer survival in Estonia and to explore the role of age at diagnosis, stage at diagnosis and tumour subsite.MethodsUsing data from the population-based Estonian Cancer Registry, we examined the relative survival of adult patients diagnosed with nine common cancers in Estonia in 1995–2006 and followed up through 2011. Excess hazard ratios (EHR) of death associated with female gender adjusted for age, stage at diagnosis and tumour subsite were estimated.ResultsA total of 20 828 male and 13 166 female cases were analysed. The main data quality indicators were similar between men and women. Women had more cases with unknown extent of disease at diagnosis. Overall, the age-adjusted 5-year relative survival ratio was higher among women than men for all studied sites, but the difference was significant for cancers of mouth and pharynx (22% units), lung (5% units), skin melanoma (17% units) and kidney (8% units). The increase in survival over time was larger for women than men for cancers of mouth and pharynx, colon, rectum, kidney and skin melanoma. In multivariate analysis, women had a significantly lower EHR of death within five years after diagnosis for five of the nine cancers studied (cancers of mouth and pharynx, stomach, lung, skin melanoma and kidney). Adjustment for stage and subsite explained some, but not all of the women’s advantage.ConclusionsWe found a significant female survival advantage in Estonia for cancers of mouth and pharynx, stomach, lung, kidney and skin melanoma. The differences in favour of women tended to increase over time as from the 1990s to the 2000s, survival improved more among women than among men. A large part of the women’s advantage is likely attributable to biological factors, but other factors, such as co-morbidities, treatment compliance or health behaviour, are also probable contributors to gender survival disparities in Estonia and merit further investigation. Our findings have implications for public health, early detection and cancer care in Estonia.
Highlights
In Estonia, women have much longer life expectancy than men
Subsites according to ICDO-3 were considered for five cancers, for which subsite may be a prognostic factor based on a priori knowledge
In this study based on data from the population-based cancer registry of Estonia, we found that women had a significant survival advantage for five of the nine common solid tumours included in the study
Summary
In Estonia, women have much longer life expectancy than men. The aim of this study was to examine sex differences in cancer survival in Estonia and to explore the role of age at diagnosis, stage at diagnosis and tumour subsite. In Estonia, health disparities between sexes are even larger, as the life expectancy at birth is 81 years for women, but only 73 years for men [2]. The aim of this study was to analyse gender differences in cancer survival in Estonia and to explore the. Innos et al BMC Cancer (2015) 15:72 role of age at diagnosis, stage at diagnosis and tumour subsite using data from the population-based Estonian Cancer Registry (ECR). The registry covers the whole country (population 1.34 million in 2009) and has population-based cancer data since 1968 [9]. Estonian cancer data have been included in the Cancer Incidence in Five Continents since Volume VI (data from 1983)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
